长效奥曲肽给药后短期内进行的肽受体放射性核素治疗
本文报告一例68岁转移性小肠神经内分泌肿瘤男性患者,接受4周期177Lu-DOTATATE肽受体放射性核素治疗。前3周期在末次奥曲肽长效释放剂给药约4周后进行,第4周期因排程沟通失误仅在末次全剂量给药48小时后进行,肿瘤摄取完全未降低。
要点
- 前3周期于末次奥曲肽长效释放剂后约4周进行,第4周期于末次全剂量后仅48小时进行。
- 第4周期肿瘤摄取完全未降低,提示长效奥曲肽未削弱177Lu-DOTATATE的肿瘤摄取。
- 作者认为该现象可能为生长抑素类似物在肽受体放射性核素治疗前无需停药的不断积累的证据增添依据。
核心结论
- 第4周期在末次全剂量奥曲肽长效释放剂后仅48小时进行,肿瘤摄取完全未降低,作者认为这可能为生长抑素类似物在肽受体放射性核素治疗前无需停药的不断积累的证据增添依据。
研究设计与样本
- 本文为病例报告,对象为一名68岁转移性小肠神经内分泌肿瘤男性患者,接受4周期177Lu-DOTATATE肽受体放射性核素治疗。
主要发现
- 前3周期在末次奥曲肽长效释放剂给药约4周后进行,第4周期因排程沟通失误仅在末次全剂量给药48小时后进行。
- 尽管第4周期与末次奥曲肽长效释放剂间隔仅48小时,肿瘤摄取完全未降低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We present a case of a 68-year-old man with metastatic small bowel neuroendocrine tumor who underwent 4 cycles of peptide receptor radionuclide therapy with 177 Lu-DOTATATE. For his first 3 cycles, therapy was performed approximately 4 weeks after his last dose of octreotide LAR. Because of miscommunication in scheduling, his fourth cycle was performed only 48 hours after his last full dose of octreotide LAR. Despite this, we found that the tumoral uptake was not reduced at all, which may add to the increasing evidence on the nonnecessity of stopping somatostatin analogs before peptide receptor radionuclide therapy.
引用
- Low HC, Tay YS, Ong SYK, et al. Peptide Receptor Radionuclide Therapy Performed Shortly After Administration of Long-Acting Octreotide. Clin Nucl Med. 2023. PMID: 37844418. doi:10.1097/RLU.0000000000004906
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。